Neobe Therapeutics

At Neobe Therapeutics we are engineering tumour-colonizing bacteria that will disrupt tumour micro environment barriers and enable immunotherapies in patients with immune-excluded tumours. Only around 20% of patients with solid tumors are estimated to currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of an immunosuppressive microenvironment that leads to the generation of immune "cold" tumours. At Neobe we are harnessing the synthetic biology toolkit to engineer tumour-colonizing bacteria that locally disrupt this microenvironment. By acting locally within the tumor, these products avoid systemic toxicities while increasing drug efficacy. Disrupting these barriers and increasing immune cell infiltration in "cold" tumours will enable the success of immunotherapies in current non-responders.